Xience Prime™ Everolimus Eluting Coronary Stent with BTK indication

Xience Prime™ BTK Everolimus Eluting Peripheral Stent System
Xience Prime™ BTK Everolimus Eluting Peripheral Stent System
Xience Prime™ BTK Everolimus Eluting Peripheral Stent System

The Next Step in BTK Efficacy.

XIENCE Prime Everolimus Eluting Coronary Stent with BTK indication is clinically proven for primary stenting of focal and long lesions and is engineered for outstanding performance.1,2

Advancing BTK efficacy

Clinically Proven

  • Excellent long-term patency (angiographic binary in-stent restenosis (>50% stenosis)) of 85.2% and 98.7% limb salvage at 1 year.3,4

Pre-procedure4
Post-procedure4
12 months post-procedure4

Engineered for outstanding performance

  • Leading MULTI-LINK stent design for exceptional acute performance, uncompromised radial force, and visibility5
  • Coating technology for reliable expansion and controlled Everolimus drug release
  • Innovative delivery system for excellent deliverability and confident deployment

Ordering Information

XIENCE Prime™ Everolimus Eluting Coronary Stent with BTK indication
Stock NumberStent
Diameter (mm)
Stent
Length (mm)
Nominal
Pressure (ATM)
RBP
(ATM)
Max Stent Expansion
Diameter (MM)
1012646-282.5288183.25
1012646-382.5388183.25
1012648-283.02810183.75
1012648-383.03810183.75
1012649-283.52810184.5
1012649-383.53810184.5
1012650-284.02810184.5
1012650-384.03810184.5

Discover Abbott’s Peripheral intervention technology


 

Abbott’s Peripheral Intervention Portfolio

References

  1. Bosiers, M et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease; J Vascular Surgery 2012;55:390-399.
  2. Bosier, M et al.Outcome of a drug eluted stent in longer below the knee lesions in patients with critical limb ischemia: J Vascular Surgery 2017;58(1):49-54
  3. M. Bosiers, DESTINY, VEITH 2010
  4. M. Bosiers, LINC 2011
  5. Tests and data on file at Abbott

 

MAT-2117132 V1.0